Premium
Large‐scale, multicenter study of cerebrospinal fluid tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer's disease
Author(s) -
Itoh Nobuo,
Arai Hiroyuki,
Urakami Katsuya,
Ishiguro Koichi,
Ohno Hideto,
Hampel Harald,
Buerger Katharina,
Wiltfang Jens,
Otto Markus,
Kretzschmar Hans,
Moeller HansJuergen,
Imagawa Masaki,
Kohno Hideki,
Nakashima Kenji,
Kuzuhara Shigeki,
Sasaki Hidetada,
Imahori Kazutomo
Publication year - 2001
Publication title -
annals of neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.764
H-Index - 296
eISSN - 1531-8249
pISSN - 0364-5134
DOI - 10.1002/ana.1054
Subject(s) - cerebrospinal fluid , medicine , dementia , biomarker , tau protein , pathology , receiver operating characteristic , alzheimer's disease , apolipoprotein e , serine , disease , phosphorylation , gastroenterology , biology , biochemistry
We surveyed a total of 570 cerebrospinal fluid (CSF) samples from a variety of diseases, including Alzheimer's disease (AD; n = 236), non‐AD‐demented and nondemented diseases (n = 239), and normal controls (n = 95) to quantitate levels of tau protein phosphorylated at serine 199 (CSF/phospho‐tau 199 ) by a recently established sandwich ELISA. The CSF/phospho‐tau 199 levels in the AD group were significantly elevated compared to those in all the other non‐AD groups. Receiver operating characteristics curves showed that the diagnostic sensitivity and specificity for the AD group versus all the other non‐AD groups using the CSF/phospho‐tau 199 were 85.2% and 85.0%, respectively. Furthermore, there was a significant positive correlation between CSF/phospho‐tau 199 and CSF/total‐tau levels in the AD group. Elevated CSF/phospho‐tau 199 in the AD group was noted irrespective of age, gender, dementia severity, and number of apolipoprotein E4 alleles. Thus, we suggest that CSF/phospho‐tau 199 may be a novel and logical biomarker in supporting antemortem diagnosis of AD.